Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 494 entries
View as:

PK & Tolerability of CNV1014802 in Young and Elderly Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02359344 Org: User:
Start: 02/03/15 End: 04/20/15 Due: 04/20/16

Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

Phase: N/A Priority: Normal
NCT ID: NCT01004081 Org: User:
Start: 11/30/09 End: 10/31/11 Due: 10/31/12

Long-Term Assessment of Remyelinating Therapy

Phase: N/A Priority: Normal
NCT ID: NCT02657915 Org: User:
Start: 03/10/16 End: 01/23/17 Due: 01/23/18

Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies

Phase: N/A Priority: Normal
NCT ID: NCT02241785 Org: User:
Start: 09/30/14 End: 05/02/16 Due: 05/02/17

An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)

Phase: N/A Priority: Normal
NCT ID: NCT03749447 Org: User:
Start: 03/08/19 End: 08/23/23 Due: 08/23/24

Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Phase: N/A Priority: Normal
NCT ID: NCT00099489 Org: User:
Start: 02/29/04 End: 02/28/06 Due: 02/28/07

JC-Virus (JCV) Antibody Program

Phase: N/A Priority: Normal
NCT ID: NCT01070823 Org: User:
Start: 03/31/10 End: 06/30/12 Due: 06/30/13

A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments

Phase: N/A Priority: Normal
NCT ID: NCT06127095 Org: User:
Start: 11/24/23 End: 11/28/24 Due: 11/28/25

Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies

Phase: N/A Priority: Normal
NCT ID: NCT00492466 Org: User:
Start: 03/31/03 End: 08/31/06 Due: 08/31/07

Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)

Phase: N/A Priority: Normal
NCT ID: NCT02323269 Org: User:
Start: 05/31/15 End: 03/31/16 Due: 03/31/17

Study of BIIB091 Formulations in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04564612 Org: User:
Start: 09/28/20 End: 09/07/22 Due: 09/07/23

Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00801125 Org: User:
Start: 12/31/08 End: - Due: -

Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)

Phase: N/A Priority: Normal
NCT ID: NCT00746941 Org: User:
Start: 01/31/09 End: 11/30/10 Due: 11/30/11

Dimethyl Fumarate (DMF) Observational Study

Phase: N/A Priority: Normal
NCT ID: NCT02047097 Org: User:
Start: 11/19/13 End: 10/31/22 Due: 10/31/23

Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera

Phase: N/A Priority: Normal
NCT ID: NCT02410278 Org: User:
Start: 03/12/15 End: 04/27/17 Due: 04/27/18

RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

Phase: N/A Priority: Normal
NCT ID: NCT02065375 Org: User:
Start: 02/28/14 End: 09/30/14 Due: 09/30/15

Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02228707 Org: User:
Start: 08/31/14 End: 05/31/16 Due: 05/31/17

Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants

Phase: N/A Priority: Normal
NCT ID: NCT04079101 Org: User:
Start: 10/02/19 End: 12/27/19 Due: 12/27/20

Natalizumab Subcutaneous Immunogenicity and Safety Study

Phase: N/A Priority: Normal
NCT ID: NCT02142192 Org: User:
Start: 12/01/14 End: 06/04/15 Due: 06/04/16

Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT00027300 Org: User:
Start: 11/30/01 End: 01/31/05 Due: 01/31/06

Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL

Phase: N/A Priority: Normal
NCT ID: NCT00344786 Org: User:
Start: 02/28/06 End: 09/30/08 Due: 09/30/09

Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802.

Phase: N/A Priority: Normal
NCT ID: NCT00908154 Org: User:
Start: 05/31/08 End: 12/31/08 Due: 12/31/09

RTA 408 Capsules in Patients With Melanoma - REVEAL

Phase: N/A Priority: Normal
NCT ID: NCT02259231 Org: User:
Start: 10/31/14 End: 07/23/18 Due: 07/23/19

A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function

Phase: N/A Priority: Normal
NCT ID: NCT03902002 Org: User:
Start: 07/19/19 End: 01/27/20 Due: 01/27/21

A Human AME Study for Omaveloxolone

Phase: N/A Priority: Normal
NCT ID: NCT03931590 Org: User:
Start: 04/11/19 End: 05/31/19 Due: 05/31/20